Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors
10 December 2020 - 12:02AM
Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company
developing next-generation vaccines for serious infectious
diseases, today announced the appointment of Margaret G. McGlynn,
R. Ph. to its board as an independent director. Ms. McGlynn brings
extensive pharmaceutical industry, vaccine and non-profit
experience to her role on the Novavax Board of Directors.
“Margie’s deep experience in vaccine
commercialization and understanding of global public health will be
invaluable as we move closer to collecting Phase 3 clinical data
and submitting NVX-CoV2373, our COVID-19 vaccine candidate, for
regulatory authorization and approval,” said Stanley C. Erck,
Novavax President and Chief Executive Officer.
Ms. McGlynn is currently President and Board
Chair for HCU Network America, an advocacy organization she founded
in 2016 that is dedicated to supporting the needs of those impacted
by the rare genetic condition homocystinuria (HCU) and related
disorders. Prior to founding HCU Network America, Ms. McGlynn
served as President and Chief Executive Officer of the
International AIDS Vaccine Initiative (IAVI), where she led
extensive partnership efforts to advance the development, global
launch and access to a broadly effective HIV vaccine. She
previously spent more than two decades at Merck, where she held
roles of increasing responsibility, including President of Merck
Vaccines and Infectious Diseases, and President, U.S. Hospital and
Specialty Products Division.
“This is a very exciting time to be joining the
Novavax Board, and I look forward to working with my fellow
directors to support Novavax’ critical priority to advance and
deploy NVX-CoV2373 globally to help end this devastating pandemic,
as well as progress the broader vaccine portfolio,” said Ms.
McGlynn.
She currently serves on the boards of directors
of Amicus Therapeutics and Vertex Pharmaceuticals. In addition to
her corporate experience, Ms. McGlynn has served as a Board member
for several non-profit organizations, including Hilleman Institute
for Developing World Vaccine Research, Gavi, the Vaccine Alliance,
the Biotechnology Innovation Organization (BIO), and Life Science
Cares Philadelphia.
Ms. McGlynn holds a Bachelor of Science degree
in pharmacy, a Master of Business Administration in marketing, and
an honorary doctorate from the State University of New York at
Buffalo.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a late-stage
biotechnology company that promotes improved health globally
through the discovery, development and commercialization of
innovative vaccines to prevent serious infectious diseases. The
Company’s proprietary recombinant technology platform combines the
power and speed of genetic engineering to efficiently produce
highly immunogenic nanoparticles designed to address urgent global
health needs. Novavax is conducting late-stage clinical trials for
NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus
that causes COVID-19. NanoFlu™, its quadrivalent influenza
nanoparticle vaccine, met all primary objectives in its pivotal
Phase 3 clinical trial in older adults and will be advanced for
regulatory submission. Both vaccine candidates incorporate Novavax’
proprietary saponin-based Matrix-M™ adjuvant to enhance the immune
response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Novavax Forward Looking Statements
Statements herein relating to the future
of Novavax and the ongoing development of its vaccine and
adjuvant products are forward-looking
statements. Novavax cautions that these forward-looking
statements are subject to numerous risks and uncertainties, which
could cause actual results to differ materially from those
expressed or implied by such statements. These risks and
uncertainties include those identified under the heading “Risk
Factors” in the Novavax Annual Report on Form 10-K for the year
ended December 31, 2019, and Quarterly Report on
Form 10-Q for the period ended September 30, 2020,
as filed with the Securities and Exchange
Commission (SEC). We caution investors not to place
considerable reliance on forward-looking statements contained in
this press release. You are encouraged to read our filings with
the SEC, available at sec.gov, for a discussion of these
and other risks and uncertainties. The forward-looking statements
in this press release speak only as of the date of this document,
and we undertake no obligation to update or revise any of the
statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
Contacts:
Investors
Erika Trahan
ir@novavax.com
240-268-2022
Media
Brandzone/KOGS Communication
Edna Kaplan
media@novavax.com
617-974-8659
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024